Ozmen Hilal Kiziltunc, Sezen Orhan, Aktan Meryem, Erdemci Burak, Alan Burcu Sağlam, Ertekin Mustafa Vecdi, Ezirmik Sinan
Department of Radiation Oncology, Ataturk University School of Medicine, Erzurum, Turkey.
Department of Radiation Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey.
Eurasian J Med. 2020 Feb;52(1):73-76. doi: 10.5152/eurasianjmed.2019.19136.
This study investigated pre- and post-treatment tumor and lymph node dimension response rates and differences between side-effect profiles in patients with locally advanced inoperable nonsmall-cell lung cancer (NSCLC) receiving radiotherapy (RT) and concurrent chemotherapy (CT).
A total of 30 inoperable patients who had not previously received RT and having a mean age of 58.73±8.65 years with sufficient hematological reserves and normal hepatic and renal functions were included in the study. Those with pleural effusion, supraventricular lymph node metastasis, and N3 lymph node involvement were excluded. Group I (n=15) received a 21-day 75 mg/m cisplatin (D1) and 15 mg/m vinorelbine (D1, D8), whereas Group II (n=15) received 45 mg/m2 paclitaxel and AUC2 carboplatin weekly. RT was administered using a linear accelerator device with the 3D conformal RT technique at 6-18 MV energy with a 1.8-2 Gy fraction for 6-7 weeks.
Patients were randomized into Group I receiving RT and concurrent cisplatin-vinorelbine and Group II receiving weekly paclitaxel-carboplatin CT. Pre- and post-treatment tumor and lymph node dimensions significantly differed in both groups (p<0.001 and p<0.01, respectively). No significant change was observed in post-RT tumor and lymph node dimensions in terms of applied CT regimens (p>0.05).
The significant response achieved with concurrent RT and CT in groups I and II in the local advanced stage of NSCLC is important for local tumor control. Responses to treatment in the group of two arms did not differ.
本研究调查了接受放疗（RT）和同步化疗（CT）的局部晚期不可切除非小细胞肺癌（NSCLC）患者治疗前后肿瘤和淋巴结尺寸的反应率以及副作用特征之间的差异。
本研究纳入了30例未曾接受过放疗、平均年龄为58.73±8.65岁、血液学储备充足且肝肾功能正常的不可切除患者。排除有胸腔积液、室上性淋巴结转移和N3淋巴结受累的患者。第一组（n = 15）接受为期21天的75mg/m顺铂（第1天）和15mg/m长春瑞滨（第1天、第8天），而第二组（n = 15）每周接受45mg/m²紫杉醇和AUC2卡铂。使用直线加速器设备采用三维适形放疗技术在6 - 18MV能量下进行放疗，每次分割剂量为1.8 - 2Gy，共进行6 - 7周。
患者被随机分为接受放疗并同步顺铂 - 长春瑞滨的第一组和接受每周紫杉醇 - 卡铂CT的第二组。两组治疗前后肿瘤和淋巴结尺寸均有显著差异（分别为p < 0.001和p < 0.01）。就应用的CT方案而言，放疗后肿瘤和淋巴结尺寸未观察到显著变化（p > 0.05）。
在NSCLC局部晚期阶段，第一组和第二组同步放疗和CT取得的显著反应对于局部肿瘤控制很重要。两组的治疗反应没有差异。
